Clinical

Expanding on IVBM insights, Robert Kratzke, MD, discusses biomarkers, NGS panels, and treatment options for early-stage NSCLC without actionable alterations.

Christina Poh confirmed that the disconnect between provider and patient experiences of shared decision-making resonates strongly with what she observes in clinical practice, noting that while care teams tend to focus on efficacy and side effect profiles, the questions patients ask most frequently are logistical in nature, underscoring that closing this gap requires not only better communication, but also more robust patient navigation support, improved coordination between academic and community settings, and clinical trial designs that better reflect the real-world follicular lymphoma patient population.

Christina Poh discussed how she counsels patients on follicular lymphoma as a chronic, relapsing-remitting disease that is highly treatable, with many patients living for years or even decades with good quality of life, while being transparent that current standard-of-care treatments are unlikely to be curative, framing this honest, forward-looking conversation as the foundation for a long-term therapeutic partnership built on realistic expectations and shared planning.

The expanded approval, based on the phase 3 WIL-33 trial, gives children with von Willebrand disease access to routine bleeding prophylaxis.

Large biobank study suggests a polygenic risk score may improve prediction of idiopathic pulmonary fibrosis diagnosis and outcomes.

Carl Regillo, MD, on missed wet AMD injections, treatment switching, and how gene therapy could ease chronic burden.

INCA033989 demonstrated spleen reductions, anemia responses, and molecular improvements in patients with mutant calreticulin–positive myelofibrosis.

The AGAVE-201 analysis found no significant bone health concerns with axatilimab in chronic GVHD, showing stable biomarkers and no increased fractures.

Secondary analysis of the STAR trial finds hypoglossal nerve stimulation cut hypoxic burden by 76.6%, even in some AHI-defined nonresponders.

Payer delays and unpredictable coverage stall mental health meds, worsening symptoms, work performance, and ER risk while forcing clinicians into inefficient trial-and-error care.

Clinicians weigh generics versus new psychiatric meds, emphasizing evidence for treatment-resistant cases, staying current, and balancing costs, side effects, and whole-person care.

The FDA advisory committee supports Moderna’s mRNA-1010 flu vaccine for adults 50-plus, with an August 5 PDUFA decision pending for mFlusiva.

Learn how tumor and liquid biopsy testing fits care—plus insurance hurdles, turnaround delays, and the push for faster NGS results.

Explore evolving biomarker testing for rare neuroendocrine carcinomas—NGS, MSI/TMB, and emerging DLL3 targets guiding new trials.

emtelligent turns unstructured data into coded clinical insights, powering payer and oncology workflows to improve trial screening, EHR-to-EDC transfer, and decisions.

Tec-Dara showed higher MRD-negative CR rates and a 3-year PFS signal in high-risk relapsed/refractory MM, with durability still under longer-term follow-up.

At ESMO GI, Merck’s next-generation KRAS-inhibitor calderasib plus EGFR-targeting cetuximab and chemotherapy produce remarkable progression-free survival results for patients with previously untreated colorectal cancer.

Real-world data show patients with MASH reach cirrhosis in just 16 months, fueling calls for wider use of fibrosis biomarkers like FIB-4.

Minhee Kang, PharmD, explains how oncology pharmacists translate clinical research into safe, coordinated cancer care.

This segment focuses on the clinical implications of the SERENA-6 trial and its evaluation of circulating tumor DNA–guided treatment switching in hormone receptor–positive, HER2-negative metastatic breast cancer. Dr. Adam Brufsky introduces the trial within the context of ongoing regulatory and clinical debate regarding biomarker-driven intervention prior to radiographic progression.

This segment examines real-world access and reimbursement considerations influencing the use of oral selective estrogen receptor degraders in hormone receptor–positive, HER2-negative metastatic breast cancer.

Minhee Kang, PharmD, discusses 3 key considerations for oncology pharmacists to improve treatment safety, patient education, and care delivery.

Phase 1 BALLI-01 data showed UCART22 induced remissions with limited severe CRS/ICANS in relapsed/refractory B-cell ALL, supporting phase 2.

In this episode, 'Streamlining Prior Authorization: Strategies for Securing Timely Access to New RRFL Regimens,' Ryan Haumschild, PharmD, MS, MBA, CPEL explores the following question:

This episode, titled 'NCCN Guidelines in Focus: Key Updates for Follicular Lymphoma and Their Impact on Formulary Decisions,' features Ryan Haumschild, PharmD, MS, MBA, CPEL discussing the following critical questions: